Advanced Proteome Therapeutics Announces Progress on Antibody-Radioisotope Conjugate Initiative

- September 13th, 2018

Advanced Proteome Therapeutics (TSXV:APC) (FSE:0E8), is pleased to report significant progress in applying the Company’s site-selective linker technology to advance the rapidly growing field of antibody-radioisotope conjugates. As quoted in the press release: APC has initiated a program to create well-defined, chemically controlled constructs that are expected to display higher selectivity and efficiency than has … Continued

Advanced Proteome Therapeutics (TSXV:APC) (FSE:0E8), is pleased to report significant progress in applying the Company’s site-selective linker technology to advance the rapidly growing field of antibody-radioisotope conjugates.

As quoted in the press release:

APC has initiated a program to create well-defined, chemically controlled constructs that are expected to display higher selectivity and efficiency than has previously been available in the field of radiopharmaceuticals.

The Company is now pleased to disclose that it has successfully created antibody-chelator conjugates site-selectively. This has been accomplished by combining the blockbuster antibody Trastuzumab, used primarily in the treatment of breast cancer, with industry standard DOTA chelators used in targeted Beta particle therapy employing Lutetium-177, as well as other radionuclides.

To the Company’s knowledge, this work provides the first examples of antibody-chelator conjugates that have been produced site-selectively by chemical modification at preferred lysine residues of the native antibody. APC’s approach has the further advantage that the chemical composition of the antibody framework itself does not require labor intensive modification prior to attachment of the chelator payload. Thus antibody-chelator conjugates can be rapidly and economically assembled. APC has filed new patents to protect this work and has begun discussions with potential partners to move development forward.

Click here to read the full press release.

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 

Leave a Reply

Your email address will not be published. Required fields are marked *